Combinations with dabrafenib (BRAF inhibitor), trametinib (MEK kinase inhibitor), and pembrolizumab (humanized antibody for cancer immunotherapy) are now in use with rosuvastatin (HMG-CoA reductase inhibitor (statins)) or BP-101 (polyamine metabolic inhibitor) against multiple cancers (Table 1). The gene discussed is MAP2K7; the disease is cancer.